Filing Flows › Acadia Pharmaceuticals (ACAD) › Q3 2025
Acadia Pharmaceuticals (ACAD) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Acadia Pharmaceuticals (ACAD) reported revenue of $279M for the third quarter 2025 (Q3 2025), +11% from a year earlier and +5% from the quarter before. Operating margin was 12.8%, net earnings $71.8M (25.8% of revenue).
Acadia Pharmaceuticals, Q3 2025: revenue $279M (+11% year over year), operating margin 12.8%, net earnings $71.8M, operating cash flow $74.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $279M | +5% | +11% |
| Operating profit | $35.8M | +10% | +13% |
| Net earnings | $71.8M | +169% | +119% |
| Operating cash flow | $74.3M | +16% | +17% |
| Free cash flow | $73.9M | +16% | +17% |
What changed
Revenue was $278.6M in Q3 2025, up 11% year over year and up 5% from the previous quarter.
Operating profit was $35.8M, a 12.8% margin (up 0.2 points year over year). Of the extra revenue versus a year earlier, 15% reached operating profit, above the 13% margin then. Total costs grew 11% against revenue growth of 11%. The fastest-growing cost line was Research & development (+32%). Net earnings were $71.8M, up 119% year over year. The effective tax rate was -61.0%.
Operating cash flow was $74.3M (up 17% year over year), 103% of net earnings. Non-cash charges added back $3.0M of depreciation and amortization and $13.2M of share-based compensation. Working capital and other items used $13.6M. Capital expenditures of $388K left free cash flow of $73.9M.
Questions
What was Acadia Pharmaceuticals' revenue in the third quarter 2025?
Acadia Pharmaceuticals (ACAD) reported revenue of $279M for the third quarter 2025 (Q3 2025), +11% from a year earlier and +5% from the quarter before.
Was Acadia Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $35.8M (12.8% of revenue) and net earnings $71.8M.